Prospective, early, intensified controll of central retinal thickness by optical coherence tomography to detect early recurrence of disease after treatment of neovascular Age-related macula degeneration (nAMD) by intravitreal injection

Prospective, early, intensified controll of central retinal thickness by optical coherence tomography to detect early recurrence of disease after treatment of neovascular Age-related macula degeneration (nAMD) by intravitreal injection - „OCT-EIFU: OCT-Early intensified follow-up“

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00010061

Enrollment

100

Registered

2016-04-04

Start date

2016-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H35.3

Interventions

Group 1: Intervention group : All patients received three additional OCT examinations (optical coherence tomography) by protocol - in Detail: an examination of both eyes on day 7 (+/- 2 days) , day 14

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with indications for treatment of exudative AMD at the Centre for Ophthalmology , which also carry out the follow-up for recurrence detection here Willingness and consent to participate in the study

Exclusion criteria

Exclusion criteria: Physical or mental conditions which make the investigation for the patient appear unreasonable ( for example, severe dementia , severe immobility , limitation of movement in the cervical spine )

Design outcomes

Primary

Measure	Time frame
Measurement of central retinal thickness (CRT) with optical coherence tomography (OCT) in micrometers on day 7, 14 and 21 after intravitreal injection for neovascular AMD	—

Secondary

Measure	Time frame
Analysis of OCT morphology in nAMD with CNV (choroidal neovascularisation) in the early phase after anti-VEGF injection	—

Countries

Germany

Contacts

Public ContactPhilip Enders

Zentrum für Augenheilkunde der Uniklinik Köln

philip.enders@uk-koeln.de0221-478-4308

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026